Johnson & Johnson (JNJ) Announces Updated Results From the Phase 3 CARTITUDE-4 Study
unknown
📅 Published: 2025-12-10 16:28
📰 Source: Yahoo
📝 Words: 57
📝 Article Content
Johnson & Johnson (NYSE:JNJ) is one of the best pharma stocks to invest in. Johnson & Johnson (NYSE:JNJ) announced on December 6 the updated results from the Phase 3 CARTITUDE-4 study that supported durable treatment-free remissions as early as second line treatment with CARVYKTI, reporting that the disease did not progress and no further treatment was […]
📄 Summary
Johnson & Johnson (NYSE:JNJ) is one of the best pharma stocks to invest in. Johnson & Johnson (NYSE:JNJ) announced on December 6 the updated results from the Phase 3 CARTITUDE-4 study that supported durable treatment-free remissions as early as second line treatment with CARVYKTI, reporting that the disease did not progress and no further treatment was […]
Scraping Metadata:
Scraped At:
Unknown
Created At:
2025-12-11 18:38:33
Updated At:
2025-12-11 18:38:33
Scraping Job ID:
N/A
Stock Mentions:
JNJ - Johnson & Johnson
Relevance: N/A
MA - Mastercard Incorporated
Relevance: N/A